FBIO
Fortress Biotech, Inc.
There isn't enough reported data to score FBIO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
FBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Unavailable |
FBIO's revenue is currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
FBIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $2.01 | +0.8% |
| Current | 0.7x | $1.99 | — |
| Fair | 0.9x | $2.32 | +17% |
| Expensive | 1x | $2.77 | +39% |
Historical ranges are pointers, not guarantees.
FBIO has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
FBIO Forward outlook
There aren't enough analyst estimates for FBIO to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
FBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $2.70 | +$3.66 |
| Q1 2026 | $3.23 | +$5.37 |
| Q4 2025 | -$0.07 | +$2.62 |
| Q3 2023 | -$12.19 | +$3.56 |
| Q2 2023 | -$15.00 | +$0.90 |
| Q1 2023 | -$15.00 | -$2.10 |
| Q4 2022 | -$14.55 | -$2.70 |
| Q3 2022 | -$15.75 | -$8.55 |
FBIO has returned to profit: it earned $2.70 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over FBIO on earnings, with more consistent year-over-year improvement.
FBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $18.7M | +14% |
| Q1 2026 | $16M | +22% |
| Q4 2025 | $16.1M | +6.3% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $16.4M | +10% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $15.1M | -24% |
| Q3 2024 | $14.6M | -58% |
FBIO's revenue is recovering but still below its 2023 peak: $19M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -53% | +169 points |
| Q1 2026 | -48% | +122 points |
| Q4 2025 | -30% | +128 points |
| Q3 2025 | -39% | +112 points |
| Q2 2025 | -222% | -36 points |
| Q1 2025 | -170% | +111 points |
| Q4 2024 | -158% | -59 points |
| Q3 2024 | -151% | -111 points |
FBIO's operating margin was −53% last quarter, up 169 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over FBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over FBIO on profitability, with a higher operating margin.
FBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $203.9M | +$223.4M |
| Q4 2025 | -$12.5M | +$363K |
| Q3 2025 | -$6.1M | +$13.9M |
| Q1 2025 | -$19.6M | +$5.8M |
| Q4 2024 | -$12.9M | +$22.1M |
| Q3 2024 | -$20.1M | -$3.3M |
| Q1 2024 | -$25.4M | +$17.8M |
| Q4 2023 | -$35M | +$13M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with FBIO at up 243%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
FBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -17% | -6.6M shares |
| 1 year | +6.6% | +2M shares |
| 3 years | +437% | +25.9M shares |
| 5 years | +527% | +26.7M shares |
FBIO has 32M diluted shares, up 6.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over FBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
FBIO Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
FBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 8.6 | Oversold |
FBIO's weekly RSI is 38 (neutral) and its Stochastic is 9 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
FBIO PE vs Healthcare Sector
| Metric | FBIO | Sector median | Relative |
|---|---|---|---|
| PE | 0.7x | 26x | 97% below |
| PE % | 15 | 29 | 14 pts below |
FBIO has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
FBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 0.5% below |
| 20 week MA | $2.56 | 22% below |
| 50 week MA | $2.84 | 30% below |
| 100 week MA | $2.49 | 20% below |
| 200 week MA | $3.62 | 45% below |
FBIO is in a downtrend: it's below all five of its weekly moving averages, and 45% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over FBIO on trend strength, trading above more of its moving averages.
FBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.1 | $51.5 | +39% |
| 2021 | $51.5 | $39.3 | -24% |
| 2022 | $39.3 | $8.25 | -79% |
| 2023 | $8.25 | $3.01 | -64% |
| 2024 | $3.01 | $2.36 | -22% |
| 2025 | $2.36 | $3.74 | +58% |
| 2026 YTD | $3.74 | $1.99 | -47% |
FBIO has finished lower in four of the last six years. It's down 47% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over FBIO on returns for 2026, with the stronger performance.